

Market Announcement

17 February 2025

PYC Therapeutics Limited (ASX: PYC) – Trading Halt

Description

The securities of PYC Therapeutics Limited ('PYC') will be placed in trading halt at the request of PYC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 19 February 2025 or when the announcement is released to the market.

Issued by

ASX Compliance

REQUEST FOR TRADING HALT

ASX Limited
Central Park
152-158 St Georges Terrace
PERTH WA 6000

By Email: tradinghaltsperth@asx.com.au

PYC Therapeutics Limited ('PYC') – Request for Trading Halt

In accordance with Listing Rule 17.1, PYC requests that an immediate trading halt be placed on its securities pending an announcement to the market regarding a proposed capital raising.

The Company anticipates that the trading halt will be lifted on or before market open on Wednesday 19 February 2025 by provision of an announcement to ASX regarding the proposed capital raising.

PYC is not aware of any reason why the trading halt should not be granted, nor of any other information relevant to this request.

Yours sincerely



Andrew Taylor
Company Secretary

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a biotechnology company creating a new generation of RNA therapies by combining its drug design capabilities with a proprietary drug delivery platform.

The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including two programs focused on inherited eye diseases and pre-clinical discovery programs focused on neurodevelopmental and kidney diseases. PYC's discovery, pre-clinical and laboratory operations are in Australia and its translational, clinical, and

regulatory operations are in the United States. For more information, visit pyctx.com, or follow us on [LinkedIn](#) and [Twitter](#).

This ASX announcement was approved and authorized for release by the Board of PYC Therapeutics Limited

CONTACT:

Investor@pyctx.com